SPR Therapeutics® Secures $25 Million in Series C Financing

September 12th, 2017 | News
picture1

SPR Therapeutics, Inc., (SPR) a private medical device company that has developed a novel neurostimulation technology for chronic and acute pain, announced today the completion of $25 million in Series C Financing.  The investment will be used to commercialize its FDA-cleared SPRINT® Peripheral Nerve Stimulation (PNS) System and to fund additional research across multiple indications including post-surgical acute pain and chronic low back pain.  A prominent family office and Frontcourt Ventures led the round.

Read more here.

Comments are closed.